Daptomycin-Nonsusceptible Staphylococcus aureus: The Role of Combination Therapy with Daptomycin and Gentamicin

被引:11
|
作者
Jiang, Jhih-Hang [1 ,2 ]
Peleg, Anton Y. [1 ,2 ,3 ,4 ]
机构
[1] Monash Univ, Monash Biomed Discovery Inst, Infect & Immun Program, Clayton, Vic 3800, Australia
[2] Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia
[3] Monash Univ, Alfred Hosp, Dept Infect Dis, Melbourne, Vic 3004, Australia
[4] Monash Univ, Cent Clin Sch, Melbourne, Vic 3004, Australia
基金
英国医学研究理事会;
关键词
S; aureus; synergy; time-kill studies; VISA; MRSA; combination therapy; VITRO PHARMACODYNAMIC MODEL; IN-VITRO; REDUCED SUSCEPTIBILITY; VANCOMYCIN; PENETRATION; RESISTANCE; RIFAMPIN; ANTIBIOTICS; BACTEREMIA; STRAINS;
D O I
10.3390/genes6041256
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Reduced susceptibility to daptomycin in Staphylococcus aureus has now been described, leading to clinical failures. Here we determined the impact of daptomycin and gentamicin combination therapy on bactericidal activity and resistance emergence using daptomycin-susceptible and -resistant isolates with mutations linked to previous daptomycin or vancomycin exposure. Enhanced killing of S. aureus was observed when gentamicin was combined with daptomycin, most commonly with daptomycin concentrations below the peak serum free-drug concentrations achieved with standard dosing. Synergy was seen with daptomycin-susceptible isolates and with isolates resistant to vancomycin and daptomycin. Combination therapy also prevented the emergence of resistance. Daptomycin and gentamicin combination therapy may provide the synergy required to prevent emergence of resistance when daptomycin levels are below peak serum concentrations as would be found in deep-seated, complicated infections.
引用
收藏
页码:1256 / 1267
页数:12
相关论文
共 50 条
  • [41] Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology
    Credito, Kim
    Lin, Gengrong
    Appelbaum, Peter C.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (04) : 1504 - 1507
  • [42] In Vitro Activities of LTX-109, a Synthetic Antimicrobial Peptide, against Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, Daptomycin-Nonsusceptible, and Linezolid-Nonsusceptible Staphylococcus aureus
    Saravolatz, Louis D.
    Pawlak, Joan
    Johnson, Leonard
    Bonilla, Hector
    Saravolatz, Louis D., II
    Fakih, Mohamad G.
    Fugelli, Anders
    Olsen, Wenche Marie
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (08) : 4478 - 4482
  • [43] In Vitro Activity of Ceftaroline against Community-Associated Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, and Daptomycin-Nonsusceptible Staphylococcus aureus Isolates
    Saravolatz, Louis
    Pawlak, Joan
    Johnson, Leonard
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (07) : 3027 - 3030
  • [44] The mode of action of daptomycin against Staphylococcus aureus
    Hobbs, J.
    Miller, K.
    Read, N.
    Chopra, I.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S53 - S53
  • [45] Use of daptomycin for treatment Staphylococcus aureus infections
    Eisenstein, Barry I.
    EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (11) : 1523 - 1536
  • [46] Impact of daptomycin resistance on Staphylococcus aureus virulence
    Cameron, David R.
    Mortin, Lawrence I.
    Rubio, Aileen
    Mylonakis, Eleftherios
    Moellering, Robert C., Jr.
    Eliopoulos, George M.
    Peleg, Anton Y.
    VIRULENCE, 2015, 6 (02) : 127 - 131
  • [47] Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
    Fowler, V. G.
    Boucher, G. W.
    Corey, G. R.
    ANNALS OF INTERNAL MEDICINE, 2007, 147 (06) : 415 - 416
  • [48] Molecular analysis of daptomycin resistance in Staphylococcus aureus
    Strommenger, B.
    Nuebel, U.
    Layer, F.
    Doetsch, A.
    Haeussler, S.
    Erdmann, F.
    Witte, W.
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2011, 301 : 21 - 21
  • [49] A Staphylococcus aureus mutant highly tolerant to daptomycin
    Mechler, L.
    Bertram, R.
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2013, 303 : 49 - 49
  • [50] Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus
    Fowler, Vance G., Jr.
    Boucher, Helen W.
    Corey, G. Ralph
    Abrutyn, Elias
    Karchmer, Adolf W.
    Rupp, Mark E.
    Levine, Donald P.
    Chambers, Henry F.
    Tally, Francis P.
    Vigliani, Gloria A.
    Cabell, Christopher H.
    Link, Arthur Stanley
    DeMeyer, Ignace
    Filler, Scott G.
    Zervos, Marcus
    Cook, Paul
    Parsonnet, Jeffrey
    Bernstein, Jack M.
    Price, Connie Savor
    Forrest, Graeme N.
    Faetkenheuer, Gerd
    Gareca, Marcelo
    Rehm, Susan J.
    Brodt, Hans Reinhardt
    Tice, Alan
    Cosgrove, Sara E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (07): : 653 - 665